CEACAM5 and non-small cell lung carcinoma: Tusamitamab ravtansine, composed of a carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5)-directed mAb conjugated to the microtubule inhibitor DM4 via a cleavable linker, was investigated for the treatment of solid tumors (eg, CEACAM5-positive NSCLC and colorectal, stomach, pancreas, breast, esophageal, and gastroesophageal junction cancer)51,53 in an open-label, dose-escalation, dose-expansion trial.